Drugs / PTX-912
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06190886 | Jun 2024 → May 2026 overdue | metastatic malignant neoplasm | Proviva Therapeutics, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PTX-912 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06190886 ↗ |
| Route | Intravenous | “via iv infusion” NCT06190886 ↗ |